Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
نویسندگان
چکیده
منابع مشابه
Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C. IL28B variants also influence the treatment response of peginterferon plus ribavirin treatment in these patients. In the present study, we examined how ITPA and IL28B genotypes have clinical impacts on treatment-induced hematotoxicities and ...
متن کاملFactors influencing therapeutic response to peginterferron plus ribavirin in the different genotypes of chronic hepatitis C
Abstract Background: Different factors like age, sex, route of infection, initial viral load, levels of liver function tests and genotypes may affect response to treatment in patients with chronic hepatitis C. The purpose of this study was to determine the role of these factors in the treatment of these patients. Methods: From 2004 to 2012, different genotypes of chronic HCV (Hepatitis C ...
متن کاملNo association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients
BACKGROUND/AIMS There are few available data regarding the association between the single nucleotide polymorphisms (SNPs) of the gene encoding interleukin 28B (IL28B) and a sustained virologic response (SVR) to peginterferon (PEG-IFN) plus ribavirin (RBV) therapy in Korean chronic hepatitis C patients. METHODS This was a retrospective cohort study of 156 patients with chronic hepatitis C viru...
متن کامل[Results of treatment with peginterferon plus ribavirin in patients with chronic hepatitis C].
BACKGROUND The current treatment recommendation for chronic hepatitis C virus infection is the combination of peginterferon and ribavirin for 24 or 48 weeks, depending on the viral genotype. The aim of the therapy is to obtain a sustained virological response. AIM To report our experience in the treatment of chronic hepatitis C. MATERIAL AND METHODS Analysis of 52 patients treated between S...
متن کاملRevisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin
BACKGROUND The current stopping rule for peginterferon/ribavirin therapy in hepatitis C virus genotype-1 (HCV-1) patients is based on an early virological response (EVR, defined as >2 log(10) viral reduction at treatment week 12). We aimed to explore rapid stopping rules at week 4. METHODS We randomly allocated 528 HCV-1 patients into training and validation sets (at a 1∶2 ratio). The interle...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Viruses
سال: 2012
ISSN: 1999-4915
DOI: 10.3390/v4081264